Immunophotonics, Inc. has strengthened its leadership team with the appointment of Jacqueline Hess to its Board of Directors. With over 30 years of experience in leading and advising heavily regulated businesses that leverage the trans-Atlantic corridor as part of their growth journey, Ms. Hess joins an already-robust slate of directors currently serving on the Board...
Diane Beatty, PhD, VP of Regulatory and Clinical Affairs, and Kelly Porterfield, Director of Clinical Operations, will be participating in the European Conference on Interventional Oncology (ECIO) in Rotterdam, Netherlands, from April 13 to 16. They will be accompanied by Lu Alleruzzo, CEO, and Tomas Hode, PhD, CIO & President. This prestigious event is one...
Lu Alleruzzo, CEO and Tomas Hode, PhD, President & CIO were honored to be invited to present at the Entrepreneurial Seminar Series hosted by The University of Oklahoma Stephenson School of Biomedical Engineering. Their presentation titled “Development and Commercialization of a Novel Immunostimulant in Combination with Local Ablation for the Treatment of Metastatic Cancers” will...
Tomas Hode, PhD, Co-Founder, CIO, and President of Immunophotonics will be attending the AngioDynamics International Life Symposium from March 27th to 29th in Barcelona, Spain. This symposium unites industry partners and clinical experts from around the world, featuring diverse backgrounds, skills, and ideas, all aimed at exploring the latest breakthrough technologies in interventional oncology. Be...
Lu Alleruzzo, CEO and Robert Arch, SVP Corporate Development at Immunophotonics, Inc. are attending the MedInvest Biotech and Pharma Investor conference which will be held on March 27 – 28, in New York City. Lu Alleruzzo and Robert Arch are presenting on March 27th at 12:25 pm. See how Immunophotonics is pioneering efforts that aim to...
Prof. Wei R. Chen, co-inventor of IP-001, Stephenson Chair, professor, and interim director of the Stephenson School of Biomedical Engineering recently chaired the international conference, “Biophotonics and Immune Responses XX,” at the Photonics West Symposium, sponsored by the International Society for Optics and Photonics (SPIE). This year marks the 20th anniversary of the Biophotonics and...
Robert Arch, SVP Corporate Development at Immunophotonics, Inc. will be attending the BIO CEO & Investor Conference which will be held on February 10 -11, 2025 in New York at the Marriott Marquis. This event is among the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. This conference presents an...
Tomas Hode, PhD, Co-Founder, CIO, and President of Immunophotonics, Inc. will be attending the SIO2025 Annual Scientific Meeting January 30 to February 3, 2025, in Las Vegas, Nevada. Tomas will be connecting with interventional oncology professionals from around the world on the latest developments in improving cancer care alongside medical, surgical and radiation oncology to...
Tomas Hode, PhD, President & CIO will attend the SPIE, the international society for optics and photonics conferences taking place from January 25 to 30 in San Francisco. This event is one of the largest gatherings focused on photonics technologies worldwide. Tomas is excited to explore the latest advancements in photothermal therapy and nanomaterials relevant...
Immunophotonics’ Tomas Hode, PhD (CIO and President) is attending Spectrum Conference, January 16 – 18, in Miami, Florida. Some of the leading experts in the field of interventional oncology will be sharing their insights on the latest advancements in the fight against cancer at this esteemed even. Tomas is excited to connect with such talented...
